Biosimilars Market Research Reports & Industry Analysis
The worldwide prescription generic drug market has stood the test of time and has endured numerous growing pains. However, it has evolved into a formidable and important participant in the complex world of health care. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market.
Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for the promotion of biosimilars is favorable in the next five years.
Biosimilars Industry Research & Market Reports
-
Growth Opportunities in Global Biosimilars Market, Forecast to 2028
... their understanding and awareness of therapeutic agents driven by biosimilar manufacturers and regulators. As the availability of information and practical data supporting the safety and effectiveness of biosimilars increases, both patients and healthcare professionals are ... Read More
-
Glycomic Therapeutics Global Market Report 2023 Including: 1) By Class: Isolated; Synthetic 2) By Structures: Glycoproteins; Targeting Sialic Acid; Proteoglycans; Targeting Glycosaminoglycans; Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans; Targeting Glycosphingolipids 3) By Mode Of Action: Inhibits Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons 4) By Indications: Thrombosis And Chemoprophylaxis; Anemia; Anti-Adhesive And Anti-Inflammatory; Cataracts; Gaucher’s Disease; Mps-1 And IV; Cancer; Alzheimer’s Disease; Influenza Type A And B Covering: F Hoffmann-La Roche Ltd.; Bayer AG; Sanofi SA; Thermo Fisher Scientific Inc.; GlaxoSmithKline plc
... Neuraminidase; Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate; Erythropoietin And Enzyme Replacement Therapy (ERT); Tissue Plasminogen Activator; Inhibits Glucosylceramide Synthase; Interleukin 1, 2 And 3; Beta And Gamma Interferons4) ... Read More
-
Remicade Biosimilar Global Market Report 2023 Including: 1) By Type: 100mg/10ml; 500mg/50ml 2) By Disease Indication: Ulcerative Colitis; Rheumatoid Arthritis; Ankylosing Spondylitis; Crohn’s Disease; Psoriatic Arthritis; Plaque Psoriasis 3) By Application: Blood Disorders; Oncology Diseases Covering: AbbVie Inc.; Novartis AG; Amgen Inc; Viatris Inc.; Teva Pharmaceutical Industries Ltd.
... Novartis AG; Amgen Inc; Viatris Inc.; Teva Pharmaceutical Industries Ltd. Remicade Biosimilar Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess ... Read More
-
Ankylosing Spondylitis Global Market Report 2023 Including: 1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Disease-Modifying Anti-Rheumatic Drugs (DMARDS); Biological Therapies; Steroids; Physical Therapies; Surgery 2) By Molecule: Biologics; Biosimilar; Small Molecules 3) By Route of Administration: Parenteral; Oral 4) By Application: Juveniles; Adults 5) By End User: Hospitals; Clinics; Research Laboratoriesrs Covering: Pfizer Inc.; Johnson & Johnson Pvt. Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
... of Administration: Parenteral; Oral4) By Application: Juveniles; Adults5) By End User: Hospitals; Clinics; Research LaboratoriesrsCovering: Pfizer Inc.; Johnson & Johnson Pvt. Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG Ankylosing Spondylitis Global Market Report ... Read More
-
Plant-based Biologics and Expression Systems Market, 2022-2035
... the COVID-19 pandemic. At present, about 85% of the drug candidates are produced using mammalian cell cultures. However, such systems are associated with a number of challenges; these include risk of introducing pathogens, concerns related ... Read More
-
Biopharmaceutical CMO Market Forecasts to 2030 – Global Analysis By Product (Biologics, Biosimilars and Other Products), Source, Service and By Geography
... in 2023 and is expected to reach $39.41 billion by 2030 growing at a CAGR of 14.6% during the forecast period. A biopharmaceutical CMO, often referred to as a contract manufacturing organization, is a business ... Read More
-
Biosimilars Market Forecasts to 2030 – Global Analysis By Drug Class (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins and Other Drug Classes), Manufacturing Type (In-house Manufacturing and Contract Manufacturing), Technology (Mass Spectroscopy, Chromatography, Monoclonal Antibody Technology and Other Technologies), Application, End User and By Geography
... and Other Technologies), Application, End User and By GeographyAccording to Stratistics MRC, the Global Biosimilars Market is accounted for $23.9 billion in 2023 and is expected to reach $100.2 billion by 2030 growing at a ... Read More
-
Europe Biosimilars Market Forecast to 2030 - Regional Analysis By Disease Indication (Cancer, Diabetes, Autoimmune Disease, and Other Disease Indication), Route of Administration (Intravenous, Subcutaneous, and Others), Drug Class (Granulocyte Colony-Stimulating Factor, Insulin, TNF Blockers and Monoclonal Antibodies, and Others), Distribution Channel (Hospital Pharmacies, Compounding Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region
... and Monoclonal Antibodies, and Others), Distribution Channel (Hospital Pharmacies, Compounding Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region The Europe biosimilars market is expected to grow from US$ 10,344.86 million in 2022 to US$ 1,15,125.91 ... Read More
-
Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
... reach US$ 14.7 Billion by 2028, exhibiting a growth rate (CAGR) of 21.6% during 2023-2028. Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation ... Read More
-
Recombinant Erythropoietin Market
... and Clinics, Dialysis Centers, Oncology Centers, Others), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 Recombinant erythropoietin (rEPO) is ... Read More
-
2023 Global Biosimilar Contract Manufacturing Industry (2029 Outlook)
... Market Outlook reports provide market size data for a three-year historical trend (2017-2020), a three-year forecast estimate trends (2021-2023), and a five-year outlook projection (2024-2029) for 46 countries. Market and product shipments include the total ... Read More
-
2023 Global Biosimilar Monoclonal Antibodies Market Industry (2029 Outlook)
... Global Advanced Market Outlook reports provide market size data for a three-year historical trend (2017-2020), a three-year forecast estimate trends (2021-2023), and a five-year outlook projection (2024-2029) for 46 countries. Market and product shipments include ... Read More
-
Global Biosimilars Market - 2023-2030
... is expected to exhibit a CAGR of 12.8% during the forecast period 2023-2030. Biosimilars provide an opportunity to increase patient access to biological therapies by offering more affordable alternatives while maintaining the same therapeutic benefits. ... Read More
-
2023 Global Forecast for Oncology Biosimilars Market (2024-2029 Outlook)-High Tech & Emerging Markets Report
... product or service category is within the NAICS Medical Laboratories industry. The product or service category is within the NAICS Medical Laboratories industry. The global market is expected to increase from USD xx billion in ... Read More
-
Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2023 - 2032
... to reach USD 7.65 billion by 2032, according to a new study by Polaris Market Research. The report “Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, ... Read More
-
Impact of Inflation on the Healthcare Sector by Physicians Perspective, Patient Treatment, Regional Analysis, Drug Prices and Treatment Costs - Thematic Intelligence
... continues to examine the impact of inflation on healthcare systems, patients, and HCPs. The report provides an overview of the current and future outlook of the healthcare sector, government policies, innovative technologies, and initiatives that ... Read More
-
Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028
... billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. Factors such as regulatory approvals, favorable reimbursement policies, rising demand for cost effective biosimilars is driving the ... Read More
-
Global Bevacizumab Monoclonal Antibody Biosimilar Market Growth 2023-2029
... to grow at a CAGR of -15.0% from 2023 to 2029. United States market for Bevacizumab Monoclonal Antibody Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Lucentis (Ranibizumab) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of -2.7% from 2023 to 2029. United States market for Lucentis (Ranibizumab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Humira Biosimilar Market Growth 2023-2029
... CAGR of 13.0% from 2023 to 2029. The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars ... Read More
-
Global Herceptin (Trastuzumab) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of 5.0% from 2023 to 2029. United States market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Enbrel (Etanercept) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of 3.4% from 2023 to 2029. United States market for Enbrel (Etanercept) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Thyrogen and Biosimilar Market Growth 2023-2029
... at a CAGR of 16.3% from 2023 to 2029. United States market for Thyrogen and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % ... Read More
-
Global Adalimumab (Humira) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of -5.3% from 2023 to 2029. The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication ... Read More
-
Global Epogen and Biosimilar Market Growth 2023-2029
... at a CAGR of -3.3% from 2023 to 2029. United States market for Epogen and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % ... Read More
Research Assistance
